Practical Geriatrics

Practical Geriatrics ›› 2025, Vol. 39 ›› Issue (3): 325-330.doi: 10.3969/j.issn.1003-9198.2025.03.026

Previous Articles    

Expert Advice on the Clinical Application of Levodopa/Carbidopa/Entacapone at Early Stage of Parkinson's Disease

Expert Guidance Writing Group for the Levodopa/Carbidopa/Entacapone in Early Parkinson's Diseas (CHEN Ling, CHENG Oumei, CUI Guiyun, HUANG Wei, LIU Chunfeng, LIU Weiguo, LIU Zhenguo, MAO Chengjie, MAO Wei, WU Yuncheng, ZHU Xiaodong, ZHENG Huifen, CHENG Xiaoyu)   

  1. The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China (CHEN Ling); The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China (CHENG Oumei); The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006, China (CUI Guiyun); The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China (HUANG Wei); The Second Affiliated Hospital of Soochow University, Suzhou 215004, China (LIU Chunfeng, MAO Chengjie, CHENG Xiaoyu); Nanjing Brain Hospital, Nanjing 210029, China (LIU Weiguo); Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China (LIU Zhenguo); Xuanwu Hospital Capital Medical University, Beijing 230012, China (MAO Wei); Shanghai General Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 210080, China (WU Yuncheng); General Hospital of Tianjin Medical University, Tianjin 300052, China (ZHU Xiaodong); The Affiliated Geriatric Hospital of Nanjing Medical University, Nanjing 210024, China (ZHENG Huifen)
  • Online:2025-03-20 Published:2025-04-03
  • Contact: LIU Chunfeng, Email: liuchunfeng@suda.edu.cn

PDF (PC)

95

Abstract: The early stage of Parkinson’s disease is a key period to improve symptoms and delay the disease progression. Levodopa/Carbidopa/Entacapone is one of the recommended drugs for the treatment of early Parkinson’s disease in the guidelines. To better standardize and guide the application of levodopa/carbidopa/entacapone in early Parkinson’s disease, the writing group has conducted a thorough analysis of both domestic and international evidence-based medicine, taking into account of the specific circumstances of clinical practice in China, and jointly discussed and formulated this expert advice. The content encompasses the optimization effects of levodopa/carbidopa/entacapone on the pharmacokinetics of traditional compound levodopa, the efficacy and safety of these medications for patients with early Parkinson’s disease, the target population, dosing regimens, management of common adverse reactions and treatment adherence, aiming to provide references for clinical standardization and rational drug use.

Key words: Parkinson's disease, early stage, entacapone, levodopa/carbidopa/entacapone, COMT inhibitors, advice

CLC Number: